A1,
A2,
B,
C1,
C2,
D,
E,
F,
G-H,
I-K,
L,
M,
N,
O,
P1,
P2,
Q-R,
S,
T,
U-V,
W-Z
Diamox Side Effects, and Drug Interactions - Acetazolamide
Diamox Side Effects, and Drug Interactions - Acetazolamide
Body as a whole: Headache, malaise, fatigue, fever, pain at injection site, flushing, growth
retardation in children, flaccid paralysis, anaphylaxis
Digestive: Gastrointestinal disturbances such as nausea, vomiting, diarrhea
Hematological/Lymphatic: Blood dyscrasias such as aplastic anemia, agranulocytosis,
leukopenia, thrombocytopenia, thrombocytopenic purpura, melena
Hepato-biliary disorders: Abnormal liver function, cholestatic jaundice, hepatic insufficiency,
fulminant hepatic necrosis
Metabolic/Nutritional: Metabolic acidosis, electrolyte imbalance, including hypokalemia,
hyponatremia, osteomalacia with long-term phenytoin therapy, loss of appetite, taste alteration,
hyper/hypoglycemia
Nervous: Drowsiness, paraesthesia (including numbness and tingling of extremities and face),
depression, excitement, ataxia, confusion, convulsions, dizziness
Skin: Allergic skin reactions including urticaria, photosensitivity, Stevens-Johnson syndrome,
toxic epidermal necrolysis
Special senses: Hearing disturbances, tinnitus, myopia
Urogenital: Crystalluria, increased risk of nephrolithiasis with long-term therapy, hematuria,
glycosuria, renal failure, polyuria
Also see PRECAUTIONS
Information for Patients
Also see PATIENT INFORMATION
DRUG INTERACTIONS
(see WARNlNGS).
DIAMOX®. modifies phenytoin metabolism with increased serum levels of phenytoin. This may
increase or enhance the occurrence of osteomalacia in some patients receiving chronic phenytoin
therapy. Caution is advised in patients receiving chronic concomitant therapy.
By decreasing the gastrointestinal absorption of primidone, DIAMOX may decrease serum
concentrations of primidone and its metabolites, with a consequent possible decrease in
anticonvulsant effect. Caution is advised when beginning, discontinuing, or changing the dose of
DIAMOX in patients receiving primidone.
Because of possible additive effects with other carbonic anhydrase inhibitors, concomitant use is
not advisable.
Acetazolamide may increase the effects of other folic acid antagonists.
Acetazolamide may increase or decrease blood glucose levels. Consideration should be taken in
patients being treated with antidiabetic agents.
Acetazolamide decreases urinary excretion of amphetamine and may enhance the magnitude and
duration of their effect.
Acetazolamide reduces urinary excretion of quinidine and may enhance its effect.
Acetazolamide may prevent the urinary antiseptic effect of methenamine.
Acetazolamide increases lithium excretion and the lithium may be decreased.
Acetazolamide and sodium bicarbonate used concurrently increases the risk of renal calculus
formation.
Acetazolamide may elevate cyclosporine levels.
top
